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Numerous drug interactions related to radiopharmaceuticals take place every day in hospitals many of 
which are not reported or detected. Information concerning this kind of reaction is not abundant, and 
nuclear medicine staff are usually overwhelmed by this information. To better understand this type of 
reaction, and to help nuclear medicine staff deal with it, a review of the literature was conducted. The results 
show that almost all of radiopharmaceuticals marketed around the world present drug interactions with a 
large variety of compounds. This suggests that a logical framework to make decisions based on reviews 
incorporating adverse reactions must be created. The review also showed that researchers undertaking 
a review of literature, or even a systematic review that incorporates drug interactions, must understand 
the rationale for the suggested methods and be able to implement them in their review. Additionally, a 
global effort should be made to report as many cases of drug interaction with radiopharmaceuticals as 
possible. With this, a complete picture of drug interactions with radiopharmaceuticals can be drawn.
Uniterms: Nuclear medicine. Radiology. Radiopharmaceuticals/drug interaction. Molecular imaging.
Diversos casos de interações medicamentosas com radiofármacos ocorrem diariamente na rotina 
hospitalar, contudo muitos deles não são notificados ou mesmo percebidos. Informações a respeito desse 
tipo de reação não é abundante e os profissionais da medicina nuclear muitas vezes estão assoberbados 
por essas informações. De modo a entender esse tipo de reação e auxiliar a medicina nuclear a lidar 
com essa situação uma revisão da literatura foi realizada. Os resultados mostraram que a totalidade 
dos radiofármacos comercializados no mundo apresentam interação medicamentosa com uma enorme 
variedade de outros medicamentos. Dessa forma sugere-se que revisões sobre radiofármacos inclua 
um capítulo sobre efeitos adversos. Além disso, um esforço mundial para notificar efeitos adversos 
deve ser realizado, pois somente dessa forma se terá um quadro real da situação referente interações 
medicamentosas com radiofármacos.
Unitermos: Medicina nuclear. Radiologia. Radiofármacos/interações medicamentosas. Imagem 
molecular.
INTRODUCTION
According to Mather (2001), radiopharmacy is 
scientifically recognized as an essential sub-specialty of 
nuclear medicine. Radiopharmaceuticals are used for two 
purposes; most importantly, is their use as diagnostic tools 
in clinical medicine. Radiopharmaceuticals also serve a 
purpose in research, both clinical and nonclinical, where 
they are used as tracers to observe or quantify biochemi-
cal or physiological processes (Tewson and Krohn 1998, 
Santos-Oliveira et al 2008).
Radiopharmaceuticals have been in use for many 
years for diagnosis and therapy of a wide variety of dise-
ases (Sampson, 2003). In the early days of radiopharmacy, 
radiopharmaceuticals were generally prepared “in-house,” 
and were not regarded as true medicines. In fact, they were, 
more often than not, prepared on the open bench where 
proper quality testing was not officially recognized.  
There is a considerable body of evidence that biodis-
tribution and pharmacokinetics of radiopharmaceuticals 
may be altered by a variety of drugs, disease conditions, 
and in some cases, surgical procedures (Hesslewood, 
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Leung 1994). Drs. Sampson and Hesslewood (1989), 
state that these unknown and unrecognized interactions 
of radiopharmaceuticals with other compounds can lead 
to a state of total disorder. 
Adverse drug reactions are a major cause of morbidi-
ty and mortality. In the United States, an estimated 701,547 
people are seen every year at emergency departments due 
to adverse drug effects (Budnitz et al. 2006). Adverse 
event reporting databases provide no valuable informa-
tion on incidence, as some events may not be recognized, 
and in many countries reporting is not mandatory. The-
refore, the total incidence of drug-radiopharmaceutical 
interactions is unknown (Santos-Oliveira et al, 2008; 
Baranowska-Kortlylewicz, 2007).
It is important to clarify the difference between drug 
interaction and adverse reaction. Ryan et al. (1996) defined 
adverse reaction to radiopharmaceuticals as any response 
to a drug which is noxious and unintended, occurring at 
doses used in man for prophylaxis, diagnosis, therapy of 
disease, or for modification of physiological function. 
Drug interaction is defined by the Food and Drug 
Administration (FDA, 2009) as drug-drug interactions 
that can lead to changed systemic exposure, resulting in 
variations in drug response of the co-administered dru-
gs. Therefore, it is important to evaluate potential drug 
interactions prior to market approval as well as during 
the postmarketing period, especially with regard to radio-
pharmaceuticals.
MATERIAL AND METHODS
The location and the selection of studies is one of 
the most important steps in a review of literature, and it is 
necessary to develop a literature search strategy based on 
key elements. The review question determines the nature 
of the search strategy. In this case our question was simple:
“Do radiopharmaceuticals present drug interactions?”
To address this question a review of the literature 
was conducted for drug interactions with radiophar-
maceuticals. We searched computerized databases on 
radiopharmaceuticals including MEDLINE, EMBASE, 
the International Pharmaceutical Abstracts and Science 
Citation Index (published from 1920 to April 2007) using 
“radiopharmaceuticals / drug interactions,” “radiophar-
maceuticals / interactions,” and several other search terms. 
This was supplemented with manual searches of major 
radiopharmacy textbooks. This review of the literature 
uses a selection of the material collected, and includes 
controlled trials, cohort studies, case-control studies and 
case series, in English, French, Deutsch and Portuguese 
languages. The difficulties in finding studies related to 
radiopharmaceutical drug interactions forced the accep-
tance of studies of lower quality. Each of the papers were 
retrieved and reviewed. 
RESULTS AND DISCUSSION
The search strategy identified forty potentially rele-
vant papers. Two reviews described more than ten related 
cases. Other authors published aspects of a single study 
in a number of related papers. Each of the publications 
included in this study was located through our search, and 
all met the inclusion criteria. 
The results are shown in Table I, which summarizes 
all of the principal studies related to radiopharmaceuticals 
and adverse reaction. In addition, this table can be used as 
a guide for all nuclear medicine staff as it is portable and 
easy to follow.
TABLE I – Summary of the compounds that might interfere with radiopharmaceuticals
Reference Compound Radiopharmaceuticals Conclusion
Fisher et al.(1977) Iodine-based
Antiseptics
Technetium-99 Positive: reduce the uptake
Sampson & Hesselwood (1989)Chlorhexidine gluconate Technetium-99 Positive: reduce the uptake
Slater et al. (1983) Syringe and catheter 
components
All radiopharmaceuticals Positive: reduce the 
radiopharmaceuticals 
concentration in the sample
Millar et al. (1983) Syringe and catheter 
components
All radiopharmaceuticals Positive: reduce the 
radiopharmaceutical 
concentration in the sample
Hladik et al. (1987) Spironolactone Iodomethylnorcholesterol-131 Positive: increase the uptake
Fischer et al. (1982) Spironolactone Iodomethylnorcholesterol-131 Positive: increase the uptake
Khafagi et al. (1991) Spironolactone Iodomethylnorcholesterol-131 Positive: increase the uptake
Gross, et al. (1981) Spironolactone Iodomethylnorcholesterol-131 Positive: decrease the uptake
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Reference Compound Radiopharmaceuticals Conclusion
Gross et al. (1981) Contraceptive Iodomethylnorcholesterol-131 Positive: increase the uptake
Sampson (1993) Cortisone Gallium-citrate-67 Positive: suppression of the 
uptake
Waxman et al. (1977) Cortisone Gallium-citrate-67 Positive: suppression of the 
uptake
Sandler et al. (1991) Etidronate or pamidronate Technetium-99-labelled-phosphate Positive: reduce the increase
Hommeyer et al. (1992) Etidronate or pamidronate Technetium-99-labelled-phosphate Positive: reduce the uptake
Hesslewood and Leung (1994) β-blockers Thallous-201 Positive: reduce the uptake
Narahara et al. (1989) β-blockers Thallous-201 Positive: reduce the uptake
Sampson (1990)  Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake
Lentle and Scott (1979)  Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake
Chacko et al. (1977)  Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake
Hegge et al. (1978)  Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake
Estorch et al. (1990) Doxorubicin Antimyosin-indium-111 Positive: reduce the uptake
Reuland et al. (1992) Doxorubicin Antimyosin-indium-111 Positive: reduce the uptake
Pope and Bratke (1981) Opioid analgesics Technetium-iminodiacetic-99m Positive: reduce the uptake
Feezer (1982) Phenobarbital and 
Bethanecol
Technetium-iminodiacetic-99m Positive: increase the excretion
Hladik et al. (1987) Antibiotics and 
corticosteroids
Labelled-leukocytes Positive: false-negative results
Chung et al. (1991) Antibiotics and 
corticosteroids
Labelled-leukocytes Negative: no interference
Datz and Thorne (1986) Antibiotics and 
corticosteroids
Labelled-leukocytes Negative: no interference
Latham et al. (1992) Dipyridamole Technetium-diethylenetriamine-pentact-
acid-99m
Positive: affect the kidney 
handling.
Bobbinet et al. (1974) Aluminium (antacids) All radiopharmaceuticals Positive: reduce the uptake.
Hesslewood and Leung 
(1994)
Iodide pharmaceuticals Iodide-131 and Iodide-123 Positive: reduce the uptake
Sternthal et al. (1980) Perchlorate and  
pertechnetate ions
Iodide-sodium-131 Positive: reduce the uptake
Dorr et al.(1993) Octreotide Indium-pentetreotide-111 Positive: reduce the uptake
Sampson (1993) Cyclosphosphamide; 
vincristine and cisplatin
Gallium-67 Positive: alters the 
pharmacokinetics
Khafagi et al.(1989) Labetalol I-MIBG-131 Reduce uptake
Gomes et al. (2001) Mitomycin C 99m Tc radiopharmaceuticals,  
99m Tc-diethylene- 
triaminepentaacetic acid  
(99mTc-DTPA), 99mTc-
dimercaptosuccinic acid  
(99mTc-DMSA), 99mTc-glucioheptonic 
acid  
(99mTc-GHA)
99mTc-DTPA:
Increased the uptake in 
pancreas, ovary, uterus, 
stomach, kidney, spleen, 
thymus, heart, lung, liver, 
thyroid and bone. 
99mTc-DMSA:
Decreased the uptake in all 
organs except brain
99mTc-GHA
Increased the uptake in liver 
and decreased in stomach, 
thymus, heart and thyroid.
Moreno et.al. (2007) Extract of Uncaria 
tomentosa
Radiobiocomplex sodium pertechnetate Increased uptake in pancreas 
and muscle
Decreased the uptake in heart.
Moreno et al. (2007) Extract of Ginko biloba Sodium pertechnetate Decreased the uptake in 
duodenum
Schroeder et al. (2007) Cigarette smoke FDG-18 Increased the uptake in lungs.
TABLE I – Summary of the compounds that might interfere with radiopharmaceuticals (continuation)
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CONCLUSION
The results showed that numerous drugs may inter-
fere with radiopharmaceutical metabolism or biodistribu-
tion, and consequently, efforts must be made to minimize 
this type of event.
Our findings (Table I) can be particularly useful for 
the daily routine of nuclear medicine staff in hospitals 
where quick guides are always welcome.
In light of our results, drug interactions with radio-
pharmaceuticals should be better documented and repor-
ted. Efforts to increase adverse event reporting, and ideally 
consolidate reports worldwide, can provide a critically ne-
eded resource for prevention of drug-radiopharmaceuticals 
interactions.
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